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CRAC motifHIV-1 Vpu antagonizes the block to particle release mediated by CD317 (BST-2/HM1.24/Tetherin) via incom-
pletely understood mechanisms. Vpu and CD317 partially reside in cholesterol-rich lipid rafts where HIV-1
budding preferentially occurs. Here we ﬁnd that lipid raft association of ectopically expressed or endogenous
CD317 was unaltered upon co-expression with Vpu or following HIV-1 infection. Similarly, Vpu's lipid raft as-
sociation remained unchanged upon expression of CD317. We identify amino acids V25 and Y29 of Vpu as
crucial for microdomain partitioning and single substitution of these amino acids resulted in Vpu variants
with markedly reduced or undetectable lipid raft association. These mutations did not affect Vpu's subcellular
distribution and binding capacity to CD317, nor its ability to downmodulate cell surface CD317 and promote
HIV-1 release from CD317-positive cells. We conclude that (i) lipid raft incorporation is dispensable for Vpu-
mediated CD317 antagonism and (ii) Vpu does not antagonize CD317 by extraction from lipid rafts.
© 2011 Elsevier Inc. All rights reserved.Introduction
CD317 (BST-2/Tetherin/HM1.24) is a broadly expressed antiviral
restriction factor that impairs the release of enveloped viruses, such
as primate lentiviruses, simple retroviruses, ﬁloviruses, arenaviruses,
rhabdoviruses and orthomyxoviruses by tethering mature virions to
the producer cell-surface (Erikson et al., 2011; Jouvenet et al., 2009;
Kaletsky et al., 2009; Mansouri et al., 2009; Neil et al., 2008; Pardieu
et al., 2010; Radoshitzky et al., 2010; Sakuma et al., 2009; Van
Damme et al., 2008; Weidner et al., 2010; Yondola et al., 2011). By di-
sulﬁde bonding CD317 forms dimers and it is believed that CD317
connects mature virions and the plasma membrane without the
physical involvement of other host cell factors (Hinz et al., 2010;
Perez-Caballero et al., 2009; Yang et al., 2010).
To overcome the restriction by CD317, HIV-1 encodes the accesso-
ry protein Vpu, which expressed in cis or trans rescues particle release
(Gofﬁnet et al., 2009, 2010; Neil et al., 2008; Tervo et al., 2011; Van
Damme et al., 2008). The mechanism by which Vpu antagonizes
CD317 remains elusive, even though some insights on how Vpu coun-
teracts CD317 have been described recently. Vpu targets CD317 toDiseases, Virology, University
idelberg, Germany. Fax: +49
(J.V. Fritz),
rights reserved.proteasomal and/or lysosomal degradation (Gofﬁnet et al., 2009;
Gupta et al., 2009; Iwabu et al., 2009; Mangeat et al., 2009; Mitchell
et al., 2009), however, depletion of cellular CD317 pools is not essen-
tial for Vpu antagonism (Dube et al., 2010; Gofﬁnet et al., 2010;
Miyagi et al., 2009; Tervo et al., 2011). Vpu also reduces cell-surface
exposure of CD317 (Dube et al., 2010; Gofﬁnet et al., 2010; Mitchell
et al., 2009; Van Damme et al., 2008), an effect that correlates in qual-
itative terms with antagonism of the CD317-imposed virion release
restriction. Vpu reduces the cell-surface population of CD317 by inhi-
biting both the anterograde transport of newly synthesized CD317
and the recycling of CD317 to the cell surface, while the kinetics of
CD317 endocytosis remain unaffected (Andrew et al., 2011; Dube et
al., 2010; Lau et al., 2011; Mitchell et al., 2009; Schmidt et al., 2011).
Moreover, Vpu physically associates with CD317 (Banning et al.,
2010; Kobayashi et al., 2011; Mangeat et al., 2009; Rong et al., 2009;
Vigan and Neil, 2010), giving rise to the current model that Vpu di-
rectly sequesters CD317 away from HIV-1 budding sites at the plasma
membrane (PM) to prevent virion tethering during HIV-1 release.
CD317 as well as Vpu partially reside in cholesterol- and
sphingolipid-rich membrane microdomains (also referred to as lipid
rafts) where HIV-1 budding preferentially occurs (Holm et al., 2003;
Kupzig et al., 2003; Lindwasser and Resh, 2002; Masuyama et al.,
2009; Nguyen and Hildreth, 2000; Ono and Freed, 2001; Rollason et
al., 2007; Ruiz et al., 2010). Lipid rafts are viewed as integration plat-
forms for many factors essential for cellular processes, such as cell sig-
naling and trafﬁcking (Brown and Rose, 1992; Li et al., 2003; Simons
and Ikonen, 1997) and are composed of lipid–lipid and lipid–protein
interactions (for review: (Lingwood and Simons, 2010)). Lipid rafts
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described within membranes of the endoplasmatic reticulum (ER),
the Golgi apparatus and the endocytic system (Browman et al.,
2006; Morrow and Parton, 2005). Due to their insolubility to non-
ionic detergents such as Triton X-100 at 4 °C, membrane rafts are
often also referred to as detergent-resistant membranes (DRMs).
CD317 is targeted to lipid rafts via its GPI anchor, which is also essen-
tial for its antiviral activity (Kupzig et al., 2003; Neil et al., 2008;
Perez-Caballero et al., 2009; Rollason et al., 2007). Interestingly, in
CHO cells defective in expression of PIGL, an ER-resident enzyme re-
quired for the addition of GPI anchors, CD317 is trapped in the ER
and cannot be detected at the PM. Reconstitution of the PIGL defect
allows CD317 to reach the PM, indicating that the GPI anchor is not
only required to direct CD317 to lipid rafts but also for efﬁcient traf-
ﬁcking of CD317 to the PM where CD317 is able to tether mature
HIV-1 viral particles to the cell surface (Perez-Caballero et al., 2009).
Since Vpu interferes with the intracellular trafﬁcking of CD317
(Dube et al., 2009, 2010; Schmidt et al., 2011) and partially resides
in lipid rafts (Ruiz et al., 2010), it is plausible that Vpu-mediated an-
tagonism of CD317 may involve alterations in the lipid raft associa-
tion of the restriction factor and/or may depend on the association
of Vpu with these speciﬁc membrane microdomains.
In support of such a scenario, a recent study reported a correlation be-
tween lipid raft association of Vpu and its antagonism of the CD317-
mediated HIV-1 release restriction (Ruiz et al., 2010). However, this
study did not analyze whether Vpu affects the lipid raft association of
CD317. Moreover, VpuW22A, the Vpu mutant described to be absent
from lipid rafts and deﬁcient in counteracting CD317 (Ruiz et al.,
2010), was shown in another study to be signiﬁcantly impaired in bind-
ing to CD317 (Vigan andNeil, 2010). Since physical interactions between
CD317 and Vpu are required for antagonism by Vpu (Gupta et al., 2009;
Kobayashi et al., 2011; Rong et al., 2009; Vigan andNeil, 2010), it remains
unclear whether VpuW22A is unable to antagonize CD317 because of its
lack in lipid raft association or of its poor binding afﬁnity to CD317.
In the current study we tested whether the lipid raft-associated Vpu
subpopulation is critically involved in CD317 antagonism and possibly
acts by displacing CD317 from such microdomains. We show that Vpu
and CD317 partially co-localized with lipid rafts in the Golgi apparatus,
however, the extent of lipid raft association of CD317 was not affected
upon overexpression of Vpu or by HIV-1 infection. Similarly, CD317 did
affect neither the extent of Vpus' association with lipid rafts nor its sub-
cellular localization. Mutagenesis of a putative cholesterol-binding motif
in Vpu resulted in Vpumutants that virtually lacked lipid raft association,
but retained the ability to associatewith and reduce cell surface exposure
of CD317. Importantly, these non-lipid raft-associated Vpu mutants dis-
played near wild-type activity in antagonism of the CD317 particle re-
lease restriction. We conclude that Vpu's association with lipid rafts is
dispensable for its role as a CD317 antagonist.
Results
Vpu and CD317 partially reside in detergent resistant membranes and
co-expression of both proteins does not inﬂuence their partitioning in
these membrane microdomains
We ﬁrst characterized the partitioning of Vpu and CD317 into lipid
rafts. For subsequent analysis of effects of Vpu on DRM partitioning of
CD317, we sought to circumvent confounding problems in the inter-
pretation of our experiments due to Vpu-induced degradation of
CD317 by using a CD317 mutant that carries lysine-to-alanine muta-
tions on positions 18 and 21 (KKAA). CD317 KKAA efﬁciently restricts
the release of HIV-1Δvpu and is readily antagonized by Vpu, but is in-
sensitive to Vpu-induced degradation (Gofﬁnet et al., 2010). To test
whether the overall lipid raft association of CD317 KKAA was compa-
rable to that of wild-type (wt) CD317, 293T cells were transfected
with an expression plasmid for HA-tagged CD317 and 24 hposttransfection, detergent-resistant membranes (DRMs) were
extracted using an established ﬂotation assay following cell lysis in
cold Triton X-100 containing buffer and Optiprep gradient ultracen-
trifugation (Rauch et al., 2008). By using this method we isolated
DRMs that were most probably depleted for tetraspanin-enriched
membrane microdomains, but contained lipid rafts and caveolae
(Zheng and Foster, 2009). Therefore, the term DRM used in this
study refers to lipid rafts and caveolae only. Eight 500 μl fractions
were collected from the top of the gradient. Since intermediate frac-
tions of these gradients are largely devoid of protein (Krautkramer
et al., 2004; Ruiz et al., 2010), equal volumes of fraction 2 (the DRM
fraction), fraction 8 (the soluble fraction (S)) and of the total cell ly-
sate (I) were analyzed by Western blotting (Figs. 1A and B). Transfer-
rin receptor (Tfr; excluded from DRMs) and Caveolin (Cav; DRM-
resident) served as quality control for the fractionation. As reported
before (Gofﬁnet et al., 2010) CD317 wt and KKAA displayed differ-
ences between the relative intensity of individual CD317 species.
These most likely reﬂect differential posttranslational modiﬁcation
but their individual occurrence does not have predictive value for
the antiviral function of CD317 and for sensitivity to Vpu (Gofﬁnet
et al., 2010). While individual protein species displayed differential
afﬁnity for the DRM fraction, analyzing the distribution of all species
together revealed that the overall distribution of both CD317 variants
between DRM and S fractions was comparable (Figs. 1A and B; 31%
versus 29% (DRM) and 69% versus 71% (S), respectively; see
Methods section for details on Western blot quantiﬁcation).
To analyze lipid raft association in the absence of detergent we
next assessed the co-localization of either CD317 KKAA or Vpu with
lipid raft markers by confocal microscopy (Figs. 1C, D and F). PM
microdomains were visualized via clustering of ﬂuorescently labeled
cholera toxin (Ctx) (Giese et al., 2006; Krautkramer et al., 2004) in
Jurkat Tag T cells transiently expressing untagged or HA-tagged
CD317 variants (Fig. 1C). Surprisingly, only a small population of
CD317 wt and KKAA partially co-localized with Ctx cluster at the
PM, irrespective of the HA tag. We therefore also investigated the lo-
calization to intracellular microdomains in 293T cells using Flotilin-
1.GFP as ubiquitous DRM marker which is enriched in the trans-
Golgi network (TGN) but can also be detected at the PM (Browman
et al., 2006) and found that CD317 KKAA (Fig. 1D; upper panels)
(and CD317 wt, data not shown) and Flotilin-1.GFP localized to the
same perinuclear area. In contrast, little overlap was observed with
Erlin-1.GFP, a DRM-resident protein localized at the endoplasmic re-
ticulum (Fig. 1D; lower panels) (Browman et al., 2006). Together,
these results suggest that the KKAA mutation has no major effect on
CD317's lipid raft association or its overall subcellular localization
and suggest that, at least in 293T cells, the majority of CD317 resides
in intracellular rather than PM rafts. Analogous DRM association ana-
lyses were conducted for Vpu. Consistent with a recent report (Ruiz et
al., 2010), approx. 20% of the total cell-associated codon-optimized
HIV-1 VpuNL4–3 (Vpu) resided in DRMs (Fig. 1E, see quantiﬁcation in
Fig. 2B, black bars) and intracellular aggregates of Vpu stained posi-
tive for Flotilin-1, but not for Erlin-1 in 293T cells (Fig. 1F).
We next tested the hypothesis that Vpu directly sequesters CD317
away from HIV-1 budding sites at the PM by altering the lipid raft as-
sociation of CD317 and analyzed DRM partitioning of Vpu and CD317
upon co-expression of both proteins. Flotation analysis of transiently
transfected 293T cells demonstrated that the relative DRM associa-
tion of both, Vpu and CD317 KKAA remained largely constant irre-
spective of whether the two proteins were expressed separately or
in combination (Fig. 2A; see also quantiﬁcation in Fig. 2B (Vpu) and
Fig. 2C (CD317 KKAA)). Co-expression also failed to shift Vpu or
CD317 to fractions in-between 2 and 8 in our ﬂotation analyses
(data not shown). In intact cells, CD317 KKAA was depleted from
the cell surface in the presence of Vpu and co-localized with the
viral protein as well as with Flotilin-1 in the TGN region (Fig. 2D:
upper panels). Only partial co-localization was observed with Erlin-
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Fig. 1. Vpu and CD317 partially reside in DRMs. (A, B) Western blot (WB) of a detergent resident membrane (DRM) ﬂotation assays of 293T cells transiently expressing HA-CD317
wt (A) or the Vpu depletion resistant mutant HA-CD317 KKAA (B). Cell lysates (cold 1% Triton X-100) were separated by Optiprep gradient ultracentrifugation, and eight fractions
were collected from the top (fraction 1) to the bottom (fraction 8) of the gradient. The DRM (fraction 2) and the soluble fraction (S) (fraction 8) were analyzed together with the
unfractionated cell lysate (I). For DRM and S, 10% of each fraction was loaded; I corresponds to 5% of the total lysate. Caveolin (Cav) and transferrin receptor (Tfr) are quality con-
trols for DRM and S fractions, respectively. The relative distribution of CD317 between DRM and S fractions was determined by Licor quantiﬁcation as indicated with the combined
total signal in both fractions set to 100%. The quantiﬁed areas are highlighted by rectangles. Within these rectangles all the bands were quantiﬁed after subtraction of a calculated
average background value for a given membrane. All visible bands are speciﬁc since no signal could be detected on mock transfected cells with the HA-antibody used to detect the
different CD317 variants (data not shown (Gofﬁnet et al., 2010; Tervo et al., 2011)). (C) Micrographs of Jurkat Tag T cells transfected with expression plasmids for the indicated
CD317 variants following raft clustering by incubation with Cholera toxin (Ctx) conjugated with Alexa 555 ﬂuorescent dye and subsequently cross-linking with anti-Ctx antibody.
Anti-CD317 and appropriate Alexa 488 coupled secondary antibodies were used to stain CD317 in green; Ctx is depicted in red. Scale bars: 10 μm. (D) Micrographs of 293T cells
transfected with expression plasmids for HA-CD317 KKAA (red) and Flotilin-1.GFP (green) or Erlin-1.GFP (green). Flotilin-1 and Erlin-1 are exclusively DRM-associated proteins
enriched in the plasma membrane and TGN or in the ER, respectively. Scale bars: 10 μm. (E) WB of a DRM ﬂotation assay of 293T cells transiently expressing codon-optimized
Vpu (Vpu). (F) Micrographs of 293T cells transfected with expression plasmids for Vpu (red) and Flotilin-1.GFP (green) or Erlin-1.GFP (green). Scale bars: 10 μm.
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Fig. 2. Co-expression of Vpu and CD317 does not inﬂuence the extent of both proteins in DRMs. (A) WB of a representative DRM ﬂotation assay of 293T cells transiently expressing
HA-CD317 KKAA and Vpu. The rectangles represent the quantiﬁed area (see legend to Fig. 1 for details). (B) Quantiﬁcation of segregation of Vpu to DRM and S fractions in the ab-
sence (black bars) or presence (grey bars) of HA-CD317 KKAA. (C) Quantiﬁcation of segregation of HA-CD317 KKAA to DRM and S fractions in the absence (black bars) or presence
(grey bars) of Vpu. In (B) and (C), the combined total signal of both fractions of the respective protein was set to 100%. Shown are mean values of three independent DRM ﬂotation
assays±SD. (D) Micrographs of 293T cells transfected with expression plasmids for Vpu (red), HA-CD317 KKAA and Flotilin-1.GFP (green) or Erlin-1.GFP (green). Scale bars: 10 μm.
36 J.V. Fritz et al. / Virology 424 (2012) 33–441 in the ER (Fig. 2D: lower panels). Thus, although Vpu and CD317
partially reside in lipid rafts and co-localize at the TGN, Vpu does
not affect the overall microdomain association of CD317. This pro-
vides evidence that Vpu does not antagonize the particle release re-
striction of CD317 by extracting the restriction factor from lipid rafts.A putative CRAC motif in the hinge region of the TM domain and the
cytosolic domain of Vpu is important for Vpu's DRM association
Next we wanted to address whether the lipid raft association of
Vpu is critical for its role as CD317 antagonist. To this end we sought
to deﬁne speciﬁc lipid raft-targeting motifs in Vpu. A highly con-
served motif in the hinge region of Vpu's transmembrane and cyto-
solic domain was identiﬁed (Fig. 3A) reminiscent of a cholesterol
recognition amino acid consensus (CRAC) motif that mediates inter-
actions with cholesterol-rich microdomains of e.g. the benzodiaze-
pine receptor (Li and Papadopoulos, 1998) or HIV-1 gp41
(Vishwanathan et al., 2008). A set of Vpu variants with mutations in
this putative CRAC motif was generated, Vpu V25G, Vpu Y29G and
the double mutant Vpu V25GY29G (Fig. 3B). DRM ﬂotation assays
performed with 293T cells transiently expressing Vpu wt or one of
the three Vpu mutants demonstrated that each of these CRAC motif
mutants displayed strongly reduced DRM association, resulting in
an up to 7-fold diminished presence of Vpu in DRMs compared to
the wt protein (Fig. 3C, quantiﬁcation in Fig. 3D).Functional characterization of putative CRAC motif Vpu mutant
To characterize these Vpu mutants lacking DRM incorporation we
ﬁrst compared their subcellular distribution to that of Vpu wt
(Fig. 4A). 293T or Jurkat Tag T cells were transfected with expression
constructs for the different Vpu variants and 24 h posttransfection
cells were ﬁxed and stained for Vpu. All Vpu mutants showed compa-
rable levels of expression and, independently of the cell type used,
displayed a subcellular localization in the perinuclear region
(Fig. 4A). This subcellular localization was indistinguishable from
that of Vpu wt and thus presumably reﬂects the localization of Vpu
to the TGN (Dube et al., 2009; Hauser et al., 2010; Schmidt et al.,
2011; Vigan and Neil, 2010). To further characterize the Vpu CRAC
motif mutants, we addressed if they co-localize with endogenous
CD317 in TZM-bl cells. Staining for Vpu and CD317 24 h post transfec-
tion with expression constructs for the different Vpu variants
revealed that Vpu wt as well as all the Vpu mutants showed partial
co-localization with CD317 in the perinuclear region (Fig. 4B).
Since the physical interaction between Vpu and CD317 is mediat-
ed by the transmembrane domains of both partners and this interac-
tion is essential for Vpu antagonism of CD317 (Gupta et al., 2009;
Kobayashi et al., 2011; Rong et al., 2009; Vigan and Neil, 2010), we
next determined if Vpu is still able to interact with CD317 when car-
rying single or double mutations in the putative CRAC motif. 293T
cells were transfected with expression constructs for either wt HA-
tagged CD317, CD317 KKAA or the Vpu-binding deﬁcient mutant
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Fig. 3. A putative CRAC motif in the hinge region of the TM domain and the cytosolic domain of Vpu is important for Vpus' DRM association. (A) Alignment of HIV-1 (group M) Vpu
amino acid sequences. In red are highlighted the conserved putative cholesterol recognition amino acid consensus (CRAC) motif, the consensus sequence of which is depicted
below. (B) Amino acid alignment of Vpu mutants used in this study. (C) WB of a representative DRM ﬂotation assay performed with 293T cells expressing either Vpu wt or the
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37J.V. Fritz et al. / Virology 424 (2012) 33–44CD317 T45IΔGI (Kobayashi et al., 2011) and the different Vpu vari-
ants. 24 h post transfection cell lysates were immunoprecipitated
with an anti-HA antibody and immunoprecipitates (IP) as well as
untreated cell lysates (I) were analyzed for the presence of Vpu and
CD317 by Western blotting (Fig. 5). As shown in Fig. 5A (left panel)
and 5B, all Vpu variants were co-immunoprecipitated with CD317
wt or CD317 KKAA with comparable efﬁciency. In contrast, none of
the Vpu variants was co-immunoprecipitated with CD317 T45IΔGI
(Fig. 5C). Since the Vpu mutant W22A was described to be
absent from lipid rafts and deﬁcient in counteracting CD317 (Ruiz et
al., 2010) we also included this Vpu W22A in our co-
immunoprecipitation analysis (Fig. 5A, right panel). In contrast to
Vpu wt and the Vpu CRAC motif mutants, binding of VpuW22A to
CD317 was signiﬁcantly reduced but not abolished. In agreement
with the report by Vigan and Neil (2010), introduction of a second
point mutation, A14L, resulted in the Vpu mutant A14LW22A that
was completely deﬁcient in binding to CD317 (Fig. 5A, right panel).
We conclude that lipid raft association is not a prerequisite for the
physical association of Vpu with CD317 and that the reported defect
of Vpu W22A in counteracting CD317 (Ruiz et al., 2010) may reﬂect
its reduced binding afﬁnity to CD317 rather than its lack in lipid raft
association.
We next employed the Vpu variants with mutations in the puta-
tive CRACmotif to analyze the relevance of Vpu's lipid raft association
for its capacity to downregulate surface levels of CD317 and CD4.
A3.01 T lymphocytes that endogenously express CD317 and CD4
were electroporated with expression constructs for either Vpu and
GFP or an empty vector and GFP. 48 h posttransfection, cells were
stained for cell-surface levels of both receptors and analyzed by
ﬂow cytometry (Dube et al., 2010; Gofﬁnet et al., 2010; Mitchell et
al., 2009; Van Damme et al., 2008). Interestingly, wt as well as mutant
Vpu proteins induced a comparable and signiﬁcant reduction of
CD317 cell-surface levels to approximately 60% of those observed inGFP-expressing control cells (Fig. 6A). A similar effect was also seen
for endogenous CD317 in HeLa-derived TZM-bl cells (data not
shown). In contrast, the integrity of the putative CRAC motif was crit-
ical for Vpu-mediated downregulation of cell-surface CD4, with the
single and double mutants displaying intermediate or abolished ac-
tivity, respectively (Fig. 6A). Thus, the putative CRAC motif mediates
lipid raft association of Vpu and affects the downregulation of cell
surface CD4 (Fig. 6C). In contrast, it is dispensable for Vpu's ability
to reduce CD317 cell-surface levels.
We next investigated these Vpu CRACmotif mutants for their abil-
ity to rescue virus release in CD317-expressing cells. To this end, 293T
cells were co-transfected with HIV-1Δvpu proviral plasmid DNA as
well as expression plasmids for HA-CD317 and Vpu. 48 h posttrans-
fection, cell culture supernatants were monitored for levels of re-
leased infectious HIV-1 in a TZM-bl reporter cell assay (Keppler et
al., 2005). CD317 expression resulted in an approximately 20-fold re-
duction in the release of infectious HIV-1Δvpu (Fig. 6B). When pro-
vided in trans, Vpu wt, as well as Vpu V25G and Vpu Y29G,
enhanced HIV-1 release approximately 10-fold (Figs. 6B and C).
Since the Vpu variants were virtually absent from lipid rafts, this re-
sult indicates that lipid raft association is not a prerequisite for antag-
onism of CD317. In contrast, HIV-1 release by the double CRAC motif
mutant was signiﬁcantly reduced (Figs. 6B and C), suggesting that
this Vpu mutant is defective in parameters in addition to lipid raft as-
sociation. Concordant Western blot analyses of lysates of the virus-
producing cells conﬁrmed similar expression of all Vpu variants test-
ed (Fig. 6B, lower panel). Consistent with previous observations and
for reasons currently unknown (Serra-Moreno et al., 2011), cell-
associated levels of p55 Gag and p24CA were diminished upon
CD317 overexpression. However, cell-associated Gag levels were con-
stant in all samples with CD317 overexpression whether or not Vpu
was co-expressed, allowing us to compare the efﬁciency of HIV-1 re-
lease between these samples. Cellular CD317 levels were decreased
293T Jurkat Tag A
wt
V25G
Y29G
V25GY29G
Vpu:
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CD317 Vpu Merge
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Y29G
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Fig. 4. Vpu wt and CRAC motif Vpu mutants display equal cellular distribution and co-localization with CD317. (A) Micrographs of 293T cells (left column) and Jurkat Tag T cells
(right column) transfected with expression plasmids for Vpu wt, Vpu V25G, Vpu Y29G, or Vpu V25GY29G. The cell peripheries as well as the nuclei are highlighted by white dashed
lines. Scale bars: 10 μm. (B) Micrographs of TZM cells transfected with expression plasmids for Vpu wt, VpuV25G, Vpu Y29G or VpuV25GY29G. 24 h posttransfection the cells were
stained for endogenous CD317 (red) and Vpu (green) using the appropriate antibodies. Scale bars: 10 μm.
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able degrees (Fig. 6B, lower panel). Thus, the degree of CD317 degra-
dation under these experimental conditions did not correlate with
the viral release enhancement activity of the Vpu variants tested.
Based on the results with Vpu variants carrying single mutations in
the putative CRAC motif we conclude that lipid raft association of
the viral protein can be dispensable for Vpu-mediated antagonism
of CD317 particle release restriction.Characterization of Vpu CRAC motif mutants in the context of HIV-1
infection
We next sought to study the impact of these Vpu CRAC motif mu-
tants in the context of HIV-1 infection and in presence of endogenous
CD317. To this end, the vpu variants were introduced into the HIV-
1NL4–3 proviral backbone, and TZM-bl cells, expressing endogenous
CD317, were infected with the corresponding viruses. Similar to our
results upon ectopic expression of Vpu, DRM ﬂotation of these
infected cells 48 h postinfection revealed a markedly reduced DRM
association of Vpu V25G relative to Vpu wt (Fig. 7A and quantiﬁcation
in Fig. 7B). Virtually no DRM association was detected for Vpu Y29G
and Vpu V25GY29G under these experimental conditions (Figs. 7A
and B). Multiple and difﬁcult to resolve bands were detected for en-
dogenous CD317 in these TZM-bl cells. All these species of endoge-
nous CD317 were generally more enriched in DRMs than ectopically
expressed HA-tagged CD317 (compare Figs. 2C and 7C, 29% versus
65% DRM association, respectively). Nevertheless and consistent
with our previous results with ectopically expressed CD317, wt ormutant Vpu did not signiﬁcantly affect the DRM association of endog-
enous CD317 (Fig. 7A, quantiﬁcation in Fig. 7C).
We next explored the ability of these provirally encoded Vpu
CRAC motif mutants to antagonize the CD317-mediated particle re-
lease restriction. Virions were produced in the presence of endoge-
nous CD317 by transfection of the different proviral constructs into
TZM-bl cells and production of infectious HIV-1 was quantiﬁed by ti-
trating the cell supernatant 48 h posttransfection (Fig. 7D). Western
blotting of lysates of the virus-producing cells documented compara-
ble cell-associated levels of Vpu and p24CA (Fig. 7D). Endogenously
expressed CD317 signiﬁcantly decreased (18×) the release of HIV-
1Δvpu compared to HIV-1wt (Fig. 7D). Despite their reduced or
fully abrogated association with DRMs, Vpu V25G and Vpu Y29G
retained almost full or complete CD317 antagonizing activity, respec-
tively, conﬁrming in the context of HIV-1 infection that DRM associa-
tion of Vpu is not a prerequisite for CD317 antagonism. In contrast,
HIV-1Vpu V25GY29G, which lacks DRM association but also bears ad-
ditional defects, was almost as sensitive to the CD317 restriction as
HIV-1Δvpu (9× less virus production relative to wt). This reduced an-
tagonism was particularly surprising since Vpu V25GY29G downre-
gulated CD317 cell-surface levels as efﬁciently as Vpu wt (Fig. 6A).
In order to test whether this effect on HIV-1Vpu V25GY29G particle
release depends on CD317, we produced viral particles in 293T cells
lacking endogenous CD317. As shown in Fig. 7E, all HIV-1 variants re-
leased equal amounts of infectious viral particles in absence of CD317
irrespective of their Vpu status and produced comparable levels of
cell-associated Vpu and p24CA. These results demonstrate that DRM
association is dispensable for the antagonism of the release restriction
imposed on HIV-1 release by endogenous CD317. They furthermore
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of an overall downregulation of the restriction factor from the surface
of virus producing cells.
Discussion
Building on reports on the association of CD317 and Vpu with lipid
rafts and the requirement of CD317's lipid raft targeting GPI anchor
for its antiviral activity (Kupzig et al., 2003; Perez-Caballero et al.,
2009; Rollason et al., 2007; Ruiz et al., 2010), the aim of this study
was to test whether incorporation of Vpu into lipid rafts is critically
involved in CD317 antagonism. As judged by DRM ﬂotation and con-
focal microscopy, lipid raft association of either ectopically expressed
or endogenous CD317 remained quantitatively unaltered by Vpu in
the context of ectopic expression or HIV-1 infection. Moreover, muta-
tion of a putative CRAC motif in Vpu resulted in variants of the viral
protein that were virtually absent from lipid rafts while retaining
full binding capacity to the restriction factor. These non-
microdomain-associated Vpu's downmodulated cell-surface CD317
levels and antagonized the CD317-mediated block to HIV-1 particle
release with efﬁciencies comparable to that of Vpu wt. We conclude
that (i) Vpu antagonism of CD317 does not extract the restriction fac-
tor from lipid rafts and (ii) lipid raft association is dispensable for its
role as a CD317 antagonist.Our results conﬁrm and expand the previous detection of fractions
of cellular pools of Vpu and CD317 in lipid rafts (Kupzig et al., 2003;
Rollason et al., 2007; Ruiz et al., 2010). Surprisingly, only a small pop-
ulation of CD317 partially co-localized with Ctx cluster at the PM and
Vpu was virtually absent from PM rafts, indicating that the majority of
lipid raft association of both proteins results from incorporation into
microdomains of intracellular vesicles/membranes. Even though the
small size of lipid rafts (10–200 nm), the resolution limits of confocal
microscopy and the lack of speciﬁc clustering protocols precluded a
reliable assessment of protein association with speciﬁc microdomains
at intracellular membranes, our co-localization studies with Flotilin-
1.GFP as ubiquitous DRM marker which is enriched in the TGN
(Browman et al., 2006) are consistent with lipid raft partitioning of
both Vpu and CD317 at the level of the TGN. While raft-targeting of
CD317 is presumably determined by its GPI anchor (Kupzig et al.,
2003), we report here that a highly conserved putative CRAC motif
embedded in the hinge region of the transmembrane domain and
the cytosolic domain of Vpu is required for its lipid raft incorporation.
This propensity may reﬂect a potential interaction of the CRAC motif
with cholesterol but, based on the reduced raft targeting of Vpu vari-
ants with mutations at additional transmembrane residues (Ruiz et
al., 2010), could also mirror “raftophilic” properties of the entire
transmembrane domain. A more detailed characterization of the na-
ture of these microdomains and the speciﬁc targeting mechanisms
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40 J.V. Fritz et al. / Virology 424 (2012) 33–44will be an interesting goal of future studies that will require more re-
ﬁned biochemical approaches beyond the Triton-X 100 based extrac-
tion protocol used herein.
Mutating two individual amino acids of the putative CRACmotif of
Vpu gave rise to the Vpu variants V25G or Y29G that displayed mark-
edly reduced DRM association or were virtually absent from DRM, re-
spectively, when expressed ectopically or from the HIV-1 provirus.
Importantly, both Vpu mutants efﬁciently associated with CD317
and downregulated cell-surface levels of CD317, allowing us to test
speciﬁcally the relevance of lipid raft association of Vpu for antago-
nism of CD317. Since both Vpu variants potently overcame the parti-
cle release restriction of ectopically expressed and endogenous
CD317 with efﬁciencies that were comparable to that of Vpu wt,
lipid raft association of Vpu is clearly not a prerequisite for CD317 an-
tagonism. In light of these results it was surprising that simultaneous
mutation of both valine and tyrosine residues (Vpu V25GY29G)
resulted in the loss-of-function of Vpu with regard to antagonism of
CD317. Since Vpu V25GY29G retains CD317 downregulation and
binding activity and the loss of DRM association alone cannot account
for its reduced CD317 antagonism, this mutant likely carries addition-
al defects in activities that have not yet been appreciated to be in-
volved in CD317 antagonism. Since Vpu V25GY29G failed to reduce
cell surface levels of CD4 and high levels of CD4 can interfere with
HIV-1 budding through enforced interactions between CD4 and theviral envelope protein (Ross et al., 1999), this inability to downregu-
late cell-surface CD4 may be involved in the observed reduction in
HIV-1 release from CD4+/CD317+ cells.
Taken together, the ﬁndings presented have implications for our
understanding of the mechanism underlying the antagonism of
CD317 by Vpu. Our current view of the antagonism mechanism can
be integrated into a model in which Vpu, by physical recruitment of
the restriction factor (Banning et al., 2010; Kobayashi et al., 2011;
Rong et al., 2009; Vigan and Neil, 2010), alters the intracellular trans-
port of newly synthesized and previously internalized pools of CD317
(Andrew et al., 2011; Dube et al., 2009, 2010; Schmidt et al., 2011) at
the levels of the TGN to reduce cell surface exposure of CD317 and
thus the restriction to particle release (Dube et al., 2010; Gofﬁnet et
al., 2009, 2010; Iwabu et al., 2009; Masuyama et al., 2009; Rong et
al., 2009; Schmidt et al., 2011; Van Damme et al., 2008; Vigan and
Neil, 2010). Within this scenario we hypothesized that these interac-
tions occur in TGN-associated lipid raft microdomains and possibly
involve quantitative alterations in lipid raft association. Our results
that the overall lipid raft association of CD317 is unaffected by Vpu
and that CD317–Vpu interactions do not depend on lipid raft incorpo-
ration of the viral protein refute this hypothesis, at least for microdo-
mains isolated by the ﬂotation approach used. In addition, it appears
that signiﬁcantly larger portions of CD317 than of Vpu reside in lipid
rafts. The antagonistic activity of Vpu is thus most likely mediated by
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servation that the physical interaction between Vpu and CD317 is
critical for Vpu antagonism, this implies that non-lipid raft-
associated Vpu can interact with lipid raft-resident CD317. Based on
the lack of altered DRM partitioning of both proteins upon co-
expression and the relatively low efﬁciency of Vpu–CD317 interac-
tions as detected by co-immunoprecipitation in steady state, Vpu–
CD317 interactions are likely to be transient. We therefore propose
that transient interactions of Vpu with CD317 at the level of the
TGN result in alterations of CD317's biological properties that, by a
yet to be deﬁned mechanism, reduce its antiviral activity even after
the dissociation from Vpu. Importantly, many reports suggest a
strong correlation between the downregulation of cell-surface
CD317 and Vpu-mediated CD317 counteraction (Dube et al., 2010;Gofﬁnet et al., 2009, 2010; Iwabu et al., 2009; Masuyama et al.,
2009; Rong et al., 2009; Schmidt et al., 2011; Van Damme et al.,
2008; Vigan and Neil, 2010), implying that reduced transport of
CD317 is the major effect of Vpu counteraction. However, Vpu
V25GY29G only moderately rescued the CD317-mediated viral re-
lease block despite its marked ability to downregulate CD317 cell-
surface levels, demonstrating that downregulation of cell-surface
CD317 by itself is not fully sufﬁcient for antagonism of the restriction
factor. This is in line with two recent studies that described a lack of
correlation between CD317 downregulation and Vpu antagonism in
certain cell systems (Kuhl et al., 2011; Miyagi et al., 2009). This sug-
gests that so far unknown qualitative changes introduced to CD317
by Vpu at the TGN can disrupt the antiviral activity of the restriction
factor. With alterations in both, intracellular transport and biological
42 J.V. Fritz et al. / Virology 424 (2012) 33–44activity, CD317 antagonism by Vpu would thus involve two indepen-
dent mechanisms.
In conclusion, this study provides several lines of evidence that
challenge the hypothesis that lipid raft association of Vpu is critical
for its antagonism of CD317-mediated restriction to HIV-1 release
and rather supports a model in which Vpu's lipid raft association is
dispensable for its role as a CD317 antagonist.
Methods
Cells, plasmids, and reagents
Jurkat Tag (JTag) and A3.01 T cells were cultivated in RPMI 1640
supplemented with 10% fetal calf serum, 1% L-glutamine, and 1% pen-
icillin–streptomycin (all from Invitrogen). 293T and TZM-bl cells
were maintained in DMEM supplemented with the identical reagents
as described for RPMI medium. Proviral plasmids pHIV-1NL4-3 wt
(BH10 Env) and pHIV-1NL4-3Δvpu (BH10 Env) were from Valerie
Bosch (Pfeiffer et al., 2006). pcDNA-Vphu, expressing a codon-
optimized, Rev-independent HIV-1NL4-3 Vpu protein (Nguyen et
al., 2004) was from Klaus Strebel. The proviral plasmids pHIV-1NL4-
3 Vpu V25G, Vpu Y29G, Vpu V25GY29G, Vpu W22A, and Vpu
A14LW22A, as well as the analogous expression constructs for
codon-optimized Vpu, were generated by site-directed mutagenesis.
Expression constructs for Erlin-1.GFP and Flotilin-1.GFP were kindly
provided by Stephen Robbins. N-terminally HA-tagged CD317 wt
and CD317 KKAA were described elsewhere (Gofﬁnet et al., 2010).
HA-tagged CD317 T45IΔGI was created by site-directed mutagenesis
by replacing threonine on position 45 by an isoleucine and deleting
glycine and isoleucine on positions 25 and 26.
The following antibodies were used: polyclonal mouse anti-
cholera toxin (anti-CTx) (Sigma Aldrich); monoclonal mouse anti-
transferrin receptor (Tfr) (clone H68.4) (Zymed Laboratories, Inc.);
allophycocyanin (APC)-conjugated mouse-anti human CD4 antibody
(clone RPA-T4; BD Bioscience); mouse anti- HM1.24/CD317
(Ishikawa et al., 1995) (5 μg/ml; Chugai Pharmaceutical); rabbit poly-
clonal anti-BST2/CD317 (kindly provided by Klaus Strebel); rabbit
polyclonal anti-Vpu (Biozol), monoclonal mouse anti-HA mAb
HA.11 (Covance), polyclonal rabbit anti-Caveolin (Cav) (BD Biosci-
ence); and sheep anti-HIV-1 p24CA antiserum (from Barbara Müller).
Secondary ﬂuorescent antibodies and Alexa Fluor 555-conjugated
CTx subunit B were obtained fromMolecular Probes or BD Bioscience,
and protease inhibitor cocktail was purchased from Sigma Aldrich.
Virion infectivity assays
293T cells (1.2×105/well) or TZM-bl cells (1×105/well) were
seeded in 12-well plates 1 day before calcium-phosphate or lipofecta-
mine (Invitrogen) transfection, respectively, of either proviral DNA
(1.2 μg, wt or Vpu-mutated variants) alone (Figs. 6D and E) or togeth-
er with pcDNA3.1-HA-CD317neo (0.1 μg) and the indicated Vpu ex-
pression constructs (0.12 μg) (Fig. 5B). Two days post-transfection
25 μl of the culture supernatants were added on TZM-bl reporter
cells cultured in 96-well and the infectivity of HIV-1 was determined
48 h after infection by analysis of ﬁreﬂy luciferase activity (Keppler et
al., 2005).
Surface-exposed receptor levels
To quantify CD4 cell surface expression, A3.01 T cells were electro-
porated with 18 μg of Vpu expression constructs and 2 μg of peGFP,
and 48 h post-transfection the cells were washed and stained in PBS
with allophycocyanin (APC)-conjugated mouse–anti human CD4 an-
tibodies (clone RPA-T4; BD Bioscience). To quantify CD317 surface-
exposure, transfected TZM-bl (0.1 μg of Vpu plasmids and 0.1 μg of
peGFP) or A3.01 T cells (18 μg of Vpu plasmids and 2 μg of peGFP)were stained 48 h posttransfection with mouse anti-HM1.24/CD317
(Ishikawa et al., 1995) (5 μg/ml; Chugai Pharmaceutical, Kanagawa,
Japan) followed by staining with goat anti-mouse (Alexa Fluor 660)
(Invitrogen). A FACSCalibur with BD CellQuest Pro 4.0.2 Software
(BD Pharmingen) was used for analysis. The MFI for surface-
exposed receptors was quantiﬁed in principle as reported (Michel et
al., 2005). Relative CD317 and CD4 cell-surface expression levels
were normalized to the values obtained for control cells transfected
with the empty vector (set to 100%).
Isolation of detergent resistant membranes (DRMs)
Detergent-resistant membranes (DRMs) were isolated by ﬂotation
experiments as described previously (Krautkramer et al., 2004). Brief-
ly, 293T cells were transfected with expression constructs for codon-
optimized Vpu wt (1.8 μg) and HA-CD317 KKAA (1.5 μg) or for Vpu
wt or Vpu variants (1.8 μg) alone using metafectene (Biontex) and in-
cubated for 24 h. A total of 106 cells were transfected for each sample.
Cells were lysed in 500 μl TXNE buffer (1% Triton X-100, 50 mM Tris
HCl [pH 7.4], 150 mM NaCl, and 5 mM EDTA) for 20 min on ice, ho-
mogenized with a Dounce homogenizer, and loaded on an Optiprep
(Life Technologies) gradient (lysates were adjusted to 40% Optiprep
and overlaid with 2.5 ml 28% Optiprep and 600 μl TXNE), followed
by ultracentrifugation (35000 rpm, 3 h, 4 °C). Eight fractions of
500 μl each were collected from the top. Fraction 2, which repre-
sented the DRM fraction, and fraction 8, which was indicative of the
soluble fraction, was used for Western blot analysis. The quality of
the ﬂotation was addressed by using Tfr (excluded from DRMs) and
Cav (incorporated in DRMs). For the DRM ﬂotation assay carried out
in TZM-bl cells, a million cells were infected with 0.8 μg of VSV-G
HIV-1NL4-3 wt (BH10 Env) or Vpu-mutant viruses and 48 h post-in-
fection the DRMs were isolated as described previously.
Cholera toxin clustering
CTx-positive clusters were generated as described before
(Krautkramer et al., 2004). A total of 107 JTag cells were transfected
by electroporation with expression plasmids for HA-tagged or
untagged CD317 variants (30 μg). 48 h post-transfection, cells were
incubated with 25 μg of Alexa 555-conjugated CTx/ml in 0.1% bovine
serum albumin-phosphate-buffered saline for 30 min at 4 °C, fol-
lowed by addition of anti-CTx antibody (30 min at 4 °C and 10 min
at 37 °C). Cells were bound to poly-L-lysine-coated coverslips
(5 min, RT), ﬁxed with 3% paraformaldehyde (10 min, RT), and
extracted with 0.1% Triton X-100 (1 min, RT). Cells were stained
using monoclonal mouse anti-CD317 (Chugai Pharmaceutics), fol-
lowed by Alexa 488-conjugated secondary antibody, and were
mounted in mowiol (Sigma Aldrich). Samples were analyzed by con-
focal laser scanning microscopy (LSM 510; Zeiss) using a 100× oil im-
mersion objective lens.
Co-precipitation assay
For co-immunoprecipitation analysis, 293T cells (3.6×105/6well)
transiently expressing Vpu wt or Vpu variants together with HA-
tagged CD317, CD317 KKAA or CD317 T45IΔGI, respectively, were
harvested 24 h post-transfection and lysed on ice for 30 min in a buff-
er containing 50 mM Tris–HCl [pH 7.4], 150 mMNaCl, 5 mM EDTA, 1%
Triton X-100, and protease inhibitor cocktail (Sigma) before clariﬁca-
tion at 4000 ×g for 6 min at 4 °C. Ten percent of each lysate was pre-
served to control for protein expression. The remaining of the cell
lysates was incubated for with mouse anti-HA antibody (Covance)
(1 h, 4 °C), prior to incubation overnight at 4 °C with pre-cleared pro-
tein G sepharose beads. Immunoprecipitates were analyzed for the
presence of Vpu and CD317 by Western blotting.
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Washed cell pellets were lysed in SDS-lysis buffer. Proteins were
separated on 12.5% SDS-PAGE and blotted to nitrocellulose mem-
branes. Blocked membranes were probed with the following primary
antibodies: sheep anti-HIV-1 p24CA antiserum (from Barbara Müll-
er), rabbit polyclonal anti-Vpu (Biozol), mouse anti-HA mAb HA.11
(Covance), monoclonal mouse anti-transferrin receptor (Tfr) (clone
H68.4) (Zymed Laboratories, Inc.), rabbit polyclonal anti-Bst2/
CD317 (provided by Klaus Strebel) and rabbit polyclonal anti Cav
(BD Bioscience). Secondary antibodies were conjugated to horserad-
ish peroxidase for ECL-based detection. For detection of proteins
with the Licor system (Odyssey® Infrared Imaging System, Biosci-
ences), HRP-conjugated secondary antibodies were replaced with an-
tibodies labeled with IRDye infrared dyes.Western blotting quantiﬁcation
The relative distribution of CD317 and Vpu between DRM and S
fractions was determined by scanning Western blot membranes
with the LI-COR imaging system that measures the infrared ﬂuores-
cent signal emitted by the infrared dyes conjugated to secondary an-
tibodies recognizing species-speciﬁc primary antibodies. Signals were
quantiﬁed using the Odyssey software (Odyssey® Infrared Imaging
System, Biosciences) following background subtraction. Each fraction
was ﬁrst individually quantiﬁed and the combined total signal from
both fractions was then set to 100%. The value obtained for the indi-
vidual DRM and S fraction for a given protein were then set relative
to this 100%. For CD317 wt or CD317 KKAA, the combined signal for
all individual CD317 species was taken into account as indicated by
boxes. The quantiﬁcation shown in Figs. 2, 3 and 7 represents the
mean value of three independent DRM ﬂotation assays, quantiﬁed
as described, with the corresponding standard deviations.Immunoﬂuorescence microscopy
293T or TZM-bl cells growing on coverglasses or Jurkat Tag T cells
adhered to poly-lysine coated coverglasses were ﬁxed with 4% PFA
and permeabilized for 2 min with 0.1% Triton X-100 in PBS. Cells
were blocked for 1 h with 1% bovine serum albumin in PBS and
stained with appropriate primary and secondary antibodies for detec-
tion of Vpu, HA, or CD317, respectively. Coverslips were mounted in
mowiol and analyzed with a Zeiss LSM510 confocal microscope
with a 100× PLAN-APO objective lens. Images were recorded with
the Zeiss proprietary software LSM5 and processed with Adobe
Photoshop 6.0.Statistical evaluation
Statistical signiﬁcance was determined using the paired Student's
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